Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804
Q1 FY25 results · Apr–Jun 2024
Aurobindo Pharma reported revenue from operations of ₹7,567.02 crore (up 10.5% from Q1 FY24) and net profit of ₹918.22 crore (up 61.2% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 7,567.02 | 6,850.52 | +10.5% | 7,580.15 | −0.2% |
| Other income | 220.93 | 116.33 | +89.9% | 135.62 | +62.9% |
| Total income | 7,787.95 | 6,966.85 | +11.8% | 7,715.77 | +0.9% |
| Profit before share of associates & JVs and tax | 1,325.28 | 814.84 | +62.6% | 1,242.56 | +6.7% |
| Share of profit/(loss) of associates & JVs | (1.39) | (2.81) | (12.66) | ||
| Net profit for the period | 918.22 | 569.71 | +61.2% | 907.35 | +1.2% |
| Attributable to shareholders of the company | 919.22 | 570.75 | +61.1% | 908.75 | +1.2% |
| EPS, basic (₹) | 15.69 | 9.74 | +61.1% | 15.51 | +1.2% |
| Net margin (%) | 12.1 | 8.3 | 12.0 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,460.09 | 2,390.82 | +2.9% | 2,894.03 | −15.0% |
| Other income | 65.32 | 94.88 | −31.2% | 122.97 | −46.9% |
| Total income | 2,525.41 | 2,485.70 | +1.6% | 3,017.00 | −16.3% |
| Profit before tax | 446.24 | 426.04 | +4.7% | 779.88 | −42.8% |
| Net profit for the period | 329.04 | 335.95 | −2.1% | 578.67 | −43.1% |
| EPS, basic (₹) | 5.62 | 5.74 | −2.1% | 9.88 | −43.1% |
| Net margin (%) | 13.4 | 14.1 | 20.0 |
Consolidated
- Filed with BSE
- 13 Aug 2024, 16:21 IST
- Board meeting
- 10 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2024, 16:21 IST
- Board meeting
- 10 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE